AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review b ...
Sanofi Ventures surpasses $1.4 billion with new capital to accelerate early-stage medical innovation
Sanofi has boosted its venture capital arm, Sanofi Ventures, with a new $625 million multi-year commitment, raising the fund’s assets under man ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback